US OptionsDetailed Quotes
DRRX241115C3000
- 0.05
- 0.000.00%
15min DelayNot Open Nov 4 16:00 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume2 Open Interest3.00Strike Price0.00Turnover356.84%IV125.93%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1517Delta0.2901Gamma27.00Leverage Ratio-0.0091Theta0.0000Rho4.09Eff Leverage0.0005Vega
Durect Stock Discussion
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
loading...
loading...
In a significant move within the biopharmaceutical industry, DURECT Corporation (DRRX) has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. This alliance, announced on March 4, 2024, is set to jointly market and commercialize the ALZET Osmotic Pumps ...
No comment yet